EP1377312A4 - Facteur letal de l'anthrax inhibant la croissance tumorale et l'angiogenese - Google Patents
Facteur letal de l'anthrax inhibant la croissance tumorale et l'angiogeneseInfo
- Publication number
- EP1377312A4 EP1377312A4 EP02725277A EP02725277A EP1377312A4 EP 1377312 A4 EP1377312 A4 EP 1377312A4 EP 02725277 A EP02725277 A EP 02725277A EP 02725277 A EP02725277 A EP 02725277A EP 1377312 A4 EP1377312 A4 EP 1377312A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- angiogenesis
- tumor growth
- inhibits tumor
- lethal factor
- anthrax lethal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27762501P | 2001-03-22 | 2001-03-22 | |
US277625P | 2001-03-22 | ||
PCT/US2002/008656 WO2002076496A1 (fr) | 2001-03-22 | 2002-03-22 | Facteur letal de l'anthrax inhibant la croissance tumorale et l'angiogenese |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1377312A1 EP1377312A1 (fr) | 2004-01-07 |
EP1377312A4 true EP1377312A4 (fr) | 2004-10-06 |
Family
ID=23061685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02725277A Withdrawn EP1377312A4 (fr) | 2001-03-22 | 2002-03-22 | Facteur letal de l'anthrax inhibant la croissance tumorale et l'angiogenese |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1377312A4 (fr) |
AU (1) | AU2002255852B2 (fr) |
CA (1) | CA2442015A1 (fr) |
WO (1) | WO2002076496A1 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002017952A2 (fr) * | 2000-09-01 | 2002-03-07 | Van Andel Institute | Inhibition de la voie de la proteine mapkkk: une strategie therapeutique selective contre les melanomes |
IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
US20070116687A1 (en) * | 2003-05-13 | 2007-05-24 | Medvet Science Pty, Ltd. | Method of modulating cellular transmigration and agents for use therein |
DE602004024536D1 (de) * | 2003-07-07 | 2010-01-21 | Van Andel Res Inst | Hemmung der tumor-angiogenese durch eine kombination von thrombospondin-1 und hemmern des vaskulären endothel-wachstumsfaktors |
CN100594212C (zh) | 2003-10-21 | 2010-03-17 | 沃纳-兰伯特公司 | N-[(r)-2,3-二羟基-丙氧基]-3,4-二氟-2-(2-氟-4-碘苯基氨基)-苯甲酰胺的多晶型物 |
UA89035C2 (ru) * | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
AT504159A1 (de) | 2006-08-16 | 2008-03-15 | Marlyn Nutraceuticals Inc | Verwendung von proteasen |
WO2009132397A1 (fr) * | 2008-05-01 | 2009-11-05 | University Of South Australia | Procédés et agents pour la modulation du taux et/ou de l'activité de la protéine hif-2 alpha |
EP2701694A4 (fr) | 2011-04-28 | 2014-10-08 | Univ Duke | Procédés de traitement d'hémoglobinopathies |
WO2013082511A1 (fr) * | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Procédés pour surmonter la résistance tumorale aux antagonistes de vegf |
US9861685B2 (en) | 2012-11-20 | 2018-01-09 | Duke University | Methods of treating hemoglobinopathies |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6147107A (en) * | 1998-12-20 | 2000-11-14 | Virginia Commonwealth University | Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5405941A (en) * | 1993-04-15 | 1995-04-11 | National Jewish Center For Immunology And Respiratory Medicine | MEKK protein, capable of phosphorylating MEK |
US5525625A (en) * | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
GB2323845A (en) * | 1997-03-31 | 1998-10-07 | Merck & Co Inc | MEK inhibiting lactones |
DE69826662T2 (de) * | 1997-07-01 | 2005-02-17 | Warner-Lambert Co. Llc | 4-brom or 4-iod-phenylamino-benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren |
AU752833B2 (en) * | 1998-04-01 | 2002-10-03 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Anthrax lethal factor is a MAPK kinase protease |
ID30250A (id) * | 1998-12-22 | 2001-11-15 | Warner Lambert Co | Kemoterapi kombinasi |
CA2349467A1 (fr) * | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Acides sulfo-hydroxamiques et sulfo-hydroxamates et leur utilisation comme inhibiteurs mk |
CN1149204C (zh) * | 1999-01-13 | 2004-05-12 | 沃尼尔·朗伯公司 | 1-杂环取代的二芳基胺 |
EP1163215A1 (fr) * | 1999-03-19 | 2001-12-19 | Du Pont Pharmaceuticals Company | Amino-thio-acrylonitriles utilises comme inhibiteurs des kinases mek |
CA2362705A1 (fr) * | 1999-03-19 | 2000-09-28 | Joseph B. Santella, Iii | N-adamant-1-yl-n'-¬4-chlorobenzothiazol-2-yl| uree utilisee dans le traitement des inflammations et comme agent de radiosensibilisation anticancereux |
GB9910577D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
GB9910580D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
-
2002
- 2002-03-22 CA CA002442015A patent/CA2442015A1/fr not_active Abandoned
- 2002-03-22 WO PCT/US2002/008656 patent/WO2002076496A1/fr not_active Application Discontinuation
- 2002-03-22 EP EP02725277A patent/EP1377312A4/fr not_active Withdrawn
- 2002-03-22 AU AU2002255852A patent/AU2002255852B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6147107A (en) * | 1998-12-20 | 2000-11-14 | Virginia Commonwealth University | Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells |
Non-Patent Citations (5)
Title |
---|
BLOOD, vol. 96, no. 11 Part 1, 16 November 2000 (2000-11-16), 42nd Annual Meeting of the American Society of Hematology;San Francisco, California, USA; December 01-05, 2000, pages 306a, ISSN: 0006-4971 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2000 (2000-11-16), BONATI ANTONIO ET AL: "Selective inhibition of MEK1 kinase downmodulates ERK activity and proliferation of AML blasts", XP002279051, Database accession no. PREV200100301863 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 1999 (1999-10-01), PRICE DAVID T ET AL: "Activation of extracellular signal-regulated kinase in human prostate cancer", XP002279050, Database accession no. PREV199900481092 * |
JOURNAL OF UROLOGY, vol. 162, no. 4, October 1999 (1999-10-01), pages 1537 - 1542, ISSN: 0022-5347 * |
See also references of WO02076496A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2442015A1 (fr) | 2002-10-03 |
EP1377312A1 (fr) | 2004-01-07 |
AU2002255852B2 (en) | 2006-11-09 |
WO2002076496A1 (fr) | 2002-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0402113A3 (en) | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof | |
AU2002352903A8 (en) | Mesoporous materials and methods | |
IL158618A0 (en) | Biological pacemaker | |
AU2002342653A8 (en) | Modified growth hormone | |
EP1478228A4 (fr) | Systemes et procedes antimicrobiens | |
EP1377312A4 (fr) | Facteur letal de l'anthrax inhibant la croissance tumorale et l'angiogenese | |
EP1368051A4 (fr) | Urocortine iii et certaines de ses utilisations | |
AU2002368228A8 (en) | Micro-organism mail sterilizer | |
GB0124735D0 (en) | Bedding improvements | |
GB2377874B (en) | Poultry feed and the use thereof | |
AU2002327026A1 (en) | Human and mouse beta-defensins, antimicrobial peptides | |
HUP0402334A3 (en) | Modified human growth hormone | |
IL160532A0 (en) | Fungicidal composition comprising pyrimethanil and iprodione | |
GB0106565D0 (en) | Growth hormone treatment | |
IL146694A0 (en) | Biologically active complex | |
EP1367123A4 (fr) | Neurotonine et utilisation | |
CA98106S (en) | Castor | |
GB0116498D0 (en) | Patio eater | |
GB0200843D0 (en) | Benzodioxinopyrroles their preparation and use | |
GB2395428B (en) | Headboard | |
NZ513772A (en) | Dual insecticide and microbiological sanitisers | |
TW516367U (en) | Structure improvement of double-layered water-storage-type flowerpot | |
HU0101919D0 (en) | Environment-frienly deterrents and preparation thereof | |
HK1048927A1 (zh) | 通氣椅 | |
CA91671S (en) | Fan body |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20031007 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040823 |
|
17Q | First examination report despatched |
Effective date: 20080320 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20091001 |